| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Ludwig Institute for Cancer Research, Lausanne Branch, and
Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland
Until now it was thought that the retrovirus mouse mammary tumor virus preferentially infects B cells, which thereafter proliferate and differentiate due to superantigen-mediated T cell help. We describe in this study that dendritic cells are infectable at levels comparable to B cells in the first days after virus injection. Moreover, IgM knockout mice have chronically deleted superantigen-reactive T cells after MMTV injection, indicating that superantigen presentation by dendritic cells is sufficient for T cell deletion. In both subsets initially only few cells were infected, but there was an exponential increase in numbers of infected B cells due to superantigen-mediated T cell help, explaining that at the peak of the response infection is almost exclusively found in B cells. The level of infection in vivo was below 1 in 1000 dendritic cells or B cells. Infection levels in freshly isolated dendritic cells from spleen, Langerhans cells from skin, or bone marrow-derived dendritic cells were compared in an in vitro infection assay. Immature dendritic cells such as Langerhans cells or bone marrow-derived dendritic cells were infected 10- to 30-fold more efficiently than mature splenic dendritic cells. Bone marrow-derived dendritic cells carrying an endogenous mouse mammary tumor virus superantigen were highly efficient at inducing a superantigen response in vivo. These results highlight the importance of professional APC and efficient T cell priming for the establishment of a persistent infection by mouse mammary tumor virus.
This article has been cited by other articles:
|
|
 |
|
  C. M. Okeoma, M. Shen, and S. R. Ross A Novel Block to Mouse Mammary Tumor Virus Infection of Lymphocytes in B10.BR Mice J. Virol., February 1, 2008; 82(3): 1314 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Case, L. Petell, L. Yurkovetskiy, A. Purdy, K. J. Savage, and T. V. Golovkina Replication of Beta- and Gammaretroviruses Is Restricted in I/LnJ Mice via the Same Genetic Mechanism J. Virol., February 1, 2008; 82(3): 1438 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Courreges, D. Burzyn, I. Nepomnaschy, I. Piazzon, and S. R. Ross Critical Role of Dendritic Cells in Mouse Mammary Tumor Virus In Vivo Infection J. Virol., April 15, 2007; 81(8): 3769 - 3777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Azar, R.-P. Sekaly, and J. Thibodeau A Defective Viral Superantigen-Presenting Phenotype in HLA-DR Transfectants Is Corrected by CIITA J. Immunol., June 15, 2005; 174(12): 7548 - 7557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Burzyn, J. C. Rassa, D. Kim, I. Nepomnaschy, S. R. Ross, and I. Piazzon Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by a Retrovirus J. Virol., January 15, 2004; 78(2): 576 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mpandi, L. A. Otten, C. Lavanchy, H. Acha-Orbea, and D. Finke Passive Immunization with Neutralizing Antibodies Interrupts the Mouse Mammary Tumor Virus Life Cycle J. Virol., September 1, 2003; 77(17): 9369 - 9377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Finke, S. A. Luther, and H. Acha-Orbea The role of neutralizing antibodies for mouse mammary tumor virus transmission and mammary cancer development PNAS, January 7, 2003; 100(1): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
